On Thursday, Neogen stock got a positive adjustment to its Relative Strength (RS) Rating, from 66 to 79.
When you're researching the best stocks to buy and watch, keep a close on eye on relative price strength.
IBD's unique RS Rating identifies market leadership by showing how a stock's price movement over the last 52 weeks measures up against that of the other stocks in our database.
Decades of market research shows that the best stocks often have an 80 or higher RS Rating as they launch their biggest runs. See if Neogen stock can continue to show renewed price strength and hit that benchmark.
Looking For The Best Stocks To Buy And Watch? Start Here
Is Neogen Stock A Buy?
Neogen stock has been rallying off the bottom since October. Now is not an ideal time to jump into the biotech stock since it isn't near a proper buy zone, but see if the stock is able to offer and clear an appropriate buy point.
Earnings growth declined last quarter from -16% to -21%, but revenue rose from 3% to 76%.
Neogen stock holds the No. 30 rank among its peers in the Medical-Products industry group. Staar Surgical and Zynex are also among the group's highest-rated stocks.
